| mapracorat (BOL-303242-X) / Bayer |
NCT01230125: Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery |
|
|
| Completed | 3 | 311 | US | Mapracorat, BOL-303242-X, Vehicle | Bausch & Lomb Incorporated | Cataract | 06/11 | 08/11 | | |
NCT01298752: Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery |
|
|
| Terminated | 3 | 177 | US | Mapracorat, BOL-303242-X, Vehicle | Bausch & Lomb Incorporated | Inflammation, Pain, Cataract | 09/11 | 11/11 | | |
NCT01591161: Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery |
|
|
| Completed | 3 | 369 | US | Mapracorat, Placebo | Bausch & Lomb Incorporated | Cataract, Inflammation, Surgery | 06/13 | 07/13 | | |
NCT01591655: Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery |
|
|
| Completed | 3 | 360 | US | Mapracorat, Vehicle | Bausch & Lomb Incorporated | Cataract, Inflammation, Surgery | 09/13 | 10/13 | | |
